October 30, 2026
Safety
New
PMDA Alert for Proper Use of Drugs: Request for Proper Use of GLP-1 Receptor Agonists and GIP/GLP-1 Receptor Agonists posted
October 29, 2026
Review
New
English Translation of Review Report: Zurzuvae
October 27, 2026
Safety
New
PMDA Risk Communications: Tapinarof,etc. posted
October 27, 2026
Safety
New
Revisions of PRECAUTIONS: Inclisiran sodium,etc.posted
October 27, 2026
Events
New
Report of PMDA-ATC GMP Inspection Seminar 2026
October 26, 2026
Review
New
List of Approved Regenerative Medical Products: April 2015 to July 2026
October 19, 2026
Review
Points to Consider for the Development of Companion Diagnostics Developed in Parallel with Anti-cancer Drugs(Early Consideration) and Quality-Related Considerations for Human Cell-Derived Extracellular Vesicle (EV) Products at the Time of Initial Clinical Trial Notification (Early Consideration) posted.
October 29, 2026
Drug
New
English Translation of Review Report: Zurzuvae
October 26, 2026
Regen.
New
List of Approved Regenerative Medical Products: April 2015 to July 2026
October 19, 2026
Points to Consider for the Development of Companion Diagnostics Developed in Parallel with Anti-cancer Drugs(Early Consideration) and Quality-Related Considerations for Human Cell-Derived Extracellular Vesicle (EV) Products at the Time of Initial Clinical Trial Notification (Early Consideration) posted.
October 30, 2026
Drug
Devices
Regen.
New
PMDA Alert for Proper Use of Drugs: Request for Proper Use of GLP-1 Receptor Agonists and GIP/GLP-1 Receptor Agonists posted
October 27, 2026
Drug
IVD
New
PMDA Risk Communications: Tapinarof,etc. posted
October 27, 2026
Drug
IVD
New
Revisions of PRECAUTIONS: Inclisiran sodium,etc.posted
Currently, there is no applicable information.
Currently, there is no applicable information.
Currently, there is no applicable information.
Please note that this site may not be accurate due to machine translation, and all files (PDF, Excel, Word, PowerPoint) are not translated.